论文信息 - Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00203h - 字舞流文

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00203h

The development of a chemical series with oral efficacy against visceral leishmaniasis is described.

S. Norval | Frederick R. C. Simeons | L. Stojanovski | K. Read | I. Gilbert | P. Wyatt | Claire J. Mackenzie | J. Fiandor | Sujatha Manthri | M. De Rycker | Maria Osuna-Cabello | Jennifer Riley | Sabrinia D Crouch | John Thomas | Y. Shishikura | Michael G. Thomas | Lorna M. MacLean | T. Miles | S. Thompson | R. F. Velasco | César Guerrero | Gloria Fra | Juan Miguel-Siles | A. Daugan | M. Ajakane | Franck Martin | Lorna Campbell

[1] Juan A. Bueren-Calabuig,et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition , 2019, Proceedings of the National Academy of Sciences.

[2] David W. Gray,et al. Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis , 2018, Journal of medicinal chemistry.

[3] S. Croft,et al. Leishmaniasis , 2018, The Lancet.

[4] Michael D. Urbaniak,et al. Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis , 2018, Nature.

[5] Max Robinson,et al. Use of Calculated Physicochemical Properties to Enhance Quantitative Response When Using Charged Aerosol Detection. , 2017, Analytical chemistry.

[6] Glen Spraggon,et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.

[7] David W. Gray,et al. Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay , 2013, Antimicrobial Agents and Chemotherapy.

[8] A. Hill,et al. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.

[9] S. Klein. The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug , 2010, The AAPS Journal.